Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
STAA 
STAAR Surgical Company (STAA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/28/2025: STAA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $25.88
1 Year Target Price $25.88
| 3 | Strong Buy |
| 0 | Buy |
| 10 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 18.66% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 11/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.31B USD | Price to earnings Ratio - | 1Y Target Price 25.88 |
Price to earnings Ratio - | 1Y Target Price 25.88 | ||
Volume (30-day avg) 14 | Beta 1.02 | 52 Weeks Range 13.50 - 30.81 | Updated Date 12/1/2025 |
52 Weeks Range 13.50 - 30.81 | Updated Date 12/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.96 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -41.79% | Operating Margin (TTM) 25.87% |
Management Effectiveness
Return on Assets (TTM) -7.88% | Return on Equity (TTM) -24.65% |
Valuation
Trailing PE - | Forward PE 69.93 | Enterprise Value 1156629392 | Price to Sales(TTM) 5.68 |
Enterprise Value 1156629392 | Price to Sales(TTM) 5.68 | ||
Enterprise Value to Revenue 5.02 | Enterprise Value to EBITDA 42.84 | Shares Outstanding 49365953 | Shares Floating 31922893 |
Shares Outstanding 49365953 | Shares Floating 31922893 | ||
Percent Insiders 0.64 | Percent Institutions 106.69 |
Upturn AI SWOT
STAAR Surgical Company
Company Overview
History and Background
STAAR Surgical Company was founded in 1982. It has evolved from a broad-based ophthalmic surgical company to focusing on refractive vision correction with its Visian ICL (Implantable Collamer Lens).
Core Business Areas
- ICL (Implantable Collamer Lens): STAAR's primary business revolves around the Visian ICL, a phakic intraocular lens used for correcting myopia, hyperopia, and astigmatism. It's a refractive procedure alternative to LASIK.
- Other Ophthalmic Products: STAAR also offers other ophthalmic products, including surgical instruments and other lenses, but the ICL business represents the majority of its revenue.
Leadership and Structure
The company is led by a CEO and a management team. The organizational structure includes departments for research and development, manufacturing, sales, marketing, and finance.
Top Products and Market Share
Key Offerings
- Visian ICL: The Visian ICL is STAAR's flagship product. It corrects refractive errors by implanting a lens in the eye. Competitors include Alcon (ALC), Johnson & Johnson (JNJ), and Bausch & Lomb (BLCO).
Market Dynamics
Industry Overview
The ophthalmic surgical market is growing, driven by an aging population and increasing prevalence of refractive errors. Technological advancements, like minimally invasive procedures, are also shaping the market.
Positioning
STAAR Surgical positions itself as a premium provider of refractive vision correction solutions, particularly for patients who are not good candidates for LASIK or who desire a reversible procedure.
Total Addressable Market (TAM)
The total addressable market for refractive surgery is estimated to be in the billions of dollars. STAAR Surgical is positioned to increase the market share with the ICL lens.
Upturn SWOT Analysis
Strengths
- Strong brand recognition for Visian ICL
- High patient satisfaction rates with ICL
- Proprietary Collamer material
- Global presence
Weaknesses
- Reliance on a single product (ICL)
- High price point compared to LASIK
- Requires skilled surgeons for implantation
- Market penetration limited by ICL market awareness
Opportunities
- Expanding into new geographic markets
- Developing new ICL designs and applications
- Increasing awareness through marketing
- Capitalizing on the growing market for refractive surgery
Threats
- Competition from LASIK and other refractive procedures
- Technological advancements could make ICL obsolete
- Economic downturns could reduce demand for elective surgery
- Adverse regulatory changes
Competitors and Market Share
Key Competitors
- ALC
- JNJ
- BLCO
Competitive Landscape
STAAR Surgicalu2019s advantage lies in its ICL technology and its focus on a specific segment of the refractive surgery market. Its disadvantage is its reliance on a single product.
Growth Trajectory and Initiatives
Historical Growth: STAAR Surgical has experienced rapid growth in recent years, driven by increasing demand for ICL.
Future Projections: Analysts expect STAAR Surgical to continue to grow, driven by expanding into new markets and increasing awareness of the ICL.
Recent Initiatives: Recent initiatives include expanding sales and marketing efforts, investing in research and development, and expanding manufacturing capacity.
Summary
STAAR Surgical is a high-growth company with a strong position in the refractive surgery market. Its reliance on a single product and high price point are potential weaknesses. The company must continue innovating and expanding into new markets to maintain its growth trajectory.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is based on available information and is not financial advice. Investment decisions should be based on your own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About STAAR Surgical Company
Exchange NASDAQ | Headquaters Lake Forest, CA, United States | ||
IPO Launch date 1983-07-15 | CEO & Director Mr. Stephen C. Farrell CFA | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 1157 | Website https://www.staar.com |
Full time employees 1157 | Website https://www.staar.com | ||
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) and laser-based procedures, such as LASIK to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.